Literature DB >> 33585529

Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study.

Pedro Kurtz1, Cassia Righy1, Monica Gadelha1, Fernando A Bozza2,3, Patricia T Bozza4, Bruno Gonçalves1, Leonardo S L Bastos5, Andre M Vale6, Luiza M Higa7, Leda Castilho8, Fabio L Monteiro7, Nestor Charris1, Fernanda Fialho1, Ricardo Turon1, Alexandro Guterres1, Renan Lyra Miranda1, Carlos Henrique de Azeredo Lima1, Vanessa de Caro1, Marco Aurelio Prazeres1, Nina Ventura1, Clara Gaspari1, Fabio Miranda1, Paulo Jose da Mata1, Margarida Pêcego9, Sheila Mateos9, Maria Esther Lopes9, Shirley Castilho9, Álvaro Oliveira9, Carla Boquimpani9, Andréa Rabello9, Josiane Lopes9, Orlando Conceição Neto9, Orlando da C Ferreira7, Amilcar Tanuri7, Paulo Niemeyer Filho1, Luiz Amorim9.   

Abstract

Background: Convalescent plasma is a potential therapeutic option for critically ill patients with coronavirus disease 19 (COVID-19), yet its efficacy remains to be determined. The aim was to investigate the effects of convalescent plasma (CP) in critically ill patients with COVID-19.
Methods: This was a single-center prospective observational study conducted in Rio de Janeiro, Brazil, from March 17th to May 30th, with final follow-up on June 30th. We included 113 laboratory-confirmed COVID-19 patients with respiratory failure. Primary outcomes were time to clinical improvement and survival within 28 days. Secondary outcomes included behavior of biomarkers and viral loads. Kaplan-Meier analyses and Cox proportional-hazards regression using propensity score with inverse-probability weighing were performed.
Results: 41 patients received CP and 72 received standard of care (SOC). Median age was 61 years (IQR 48-68), disease duration was 10 days (IQR 6-13), and 86% were mechanically ventilated. At least 29 out of 41CP-recipients had baseline IgG titers ≥ 1:1,080. Clinical improvement within 28 days occurred in 19 (46%) CP-treated patients, as compared to 23 (32%) in the SOC group [adjusted hazard ratio (aHR) 0.91 (0.49-1.69)]. There was no significant change in 28-day mortality (CP 49% vs. SOC 56%; aHR 0.90 [0.52-1.57]). Biomarker assessment revealed reduced inflammatory activity and increased lymphocyte count after CP. Conclusions: In this study, CP was not associated with clinical improvement or increase in 28-day survival. However, our study may have been underpowered and included patients with high IgG titers and life-threatening disease. Clinical Trial Registration: The study protocol was retrospectively registered at the Brazilian Registry of Clinical Trials (ReBEC) with the identification RBR-4vm3yy (http://www.ensaiosclinicos.gov.br).
Copyright © 2021 Kurtz, Righy, Gadelha, Bozza, Bozza, Gonçalves, Bastos, Vale, Higa, Castilho, Monteiro, Charris, Fialho, Turon, Guterres, Lyra Miranda, de Azeredo Lima, de Caro, Prazeres, Ventura, Gaspari, Miranda, Jose da Mata, Pêcego, Mateos, Lopes, Castilho, Oliveira, Boquimpani, Rabello, Lopes, Neto, Ferreira, Tanuri, Filho and Amorim.

Entities:  

Keywords:  COVID-19; acute respiratory distress syndrome; convalescent plasma; coronavirus; survival

Year:  2021        PMID: 33585529      PMCID: PMC7876445          DOI: 10.3389/fmed.2021.630982

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  26 in total

1.  Early safety indicators of COVID-19 convalescent plasma in 5,000 patients.

Authors:  Michael J Joyner; R Scott Wright; DeLisa Fairweather; Jonathon W Senefeld; Katelyn A Bruno; Stephen A Klassen; Rickey E Carter; Allan M Klompas; Chad C Wiggins; John Ra Shepherd; Robert F Rea; Emily R Whelan; Andrew J Clayburn; Matthew R Spiegel; Patrick W Johnson; Elizabeth R Lesser; Sarah E Baker; Kathryn F Larson; Juan G Ripoll; Kylie J Andersen; David O Hodge; Katie L Kunze; Matthew R Buras; Matthew Np Vogt; Vitaly Herasevich; Joshua J Dennis; Riley J Regimbal; Philippe R Bauer; Janis E Blair; Camille M van Buskirk; Jeffrey L Winters; James R Stubbs; Nigel S Paneth; Nicole C Verdun; Peter Marks; Arturo Casadevall
Journal:  J Clin Invest       Date:  2020-06-11       Impact factor: 14.808

2.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.

Authors:  J L Vincent; R Moreno; J Takala; S Willatts; A De Mendonça; H Bruining; C K Reinhart; P M Suter; L G Thijs
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

3.  Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US.

Authors:  Shruti Gupta; Salim S Hayek; Wei Wang; Lili Chan; Kusum S Mathews; Michal L Melamed; Samantha K Brenner; Amanda Leonberg-Yoo; Edward J Schenck; Jared Radbel; Jochen Reiser; Anip Bansal; Anand Srivastava; Yan Zhou; Anne Sutherland; Adam Green; Alexandre M Shehata; Nitender Goyal; Anitha Vijayan; Juan Carlos Q Velez; Shahzad Shaefi; Chirag R Parikh; Justin Arunthamakun; Ambarish M Athavale; Allon N Friedman; Samuel A P Short; Zoe A Kibbelaar; Samah Abu Omar; Andrew J Admon; John P Donnelly; Hayley B Gershengorn; Miguel A Hernán; Matthew W Semler; David E Leaf
Journal:  JAMA Intern Med       Date:  2020-11-01       Impact factor: 21.873

4.  Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.

Authors:  Judith A Aberg; Nicole M Bouvier; Sean T H Liu; Hung-Mo Lin; Ian Baine; Ania Wajnberg; Jeffrey P Gumprecht; Farah Rahman; Denise Rodriguez; Pranai Tandon; Adel Bassily-Marcus; Jeffrey Bander; Charles Sanky; Amy Dupper; Allen Zheng; Freddy T Nguyen; Fatima Amanat; Daniel Stadlbauer; Deena R Altman; Benjamin K Chen; Florian Krammer; Damodara Rao Mendu; Adolfo Firpo-Betancourt; Matthew A Levin; Emilia Bagiella; Arturo Casadevall; Carlos Cordon-Cardo; Jeffrey S Jhang; Suzanne A Arinsburg; David L Reich
Journal:  Nat Med       Date:  2020-09-15       Impact factor: 53.440

5.  Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.

Authors:  Giacomo Grasselli; Massimiliano Greco; Alberto Zanella; Giovanni Albano; Massimo Antonelli; Giacomo Bellani; Ezio Bonanomi; Luca Cabrini; Eleonora Carlesso; Gianpaolo Castelli; Sergio Cattaneo; Danilo Cereda; Sergio Colombo; Antonio Coluccello; Giuseppe Crescini; Andrea Forastieri Molinari; Giuseppe Foti; Roberto Fumagalli; Giorgio Antonio Iotti; Thomas Langer; Nicola Latronico; Ferdinando Luca Lorini; Francesco Mojoli; Giuseppe Natalini; Carla Maria Pessina; Vito Marco Ranieri; Roberto Rech; Luigia Scudeller; Antonio Rosano; Enrico Storti; B Taylor Thompson; Marcello Tirani; Pier Giorgio Villani; Antonio Pesenti; Maurizio Cecconi
Journal:  JAMA Intern Med       Date:  2020-10-01       Impact factor: 21.873

6.  Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.

Authors:  Sarah J Valk; Vanessa Piechotta; Khai Li Chai; Carolyn Doree; Ina Monsef; Erica M Wood; Abigail Lamikanra; Catherine Kimber; Zoe McQuilten; Cynthia So-Osman; Lise J Estcourt; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-05-14

7.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients.

Authors:  Kai Duan; Bende Liu; Cesheng Li; Huajun Zhang; Ting Yu; Jieming Qu; Min Zhou; Li Chen; Shengli Meng; Yong Hu; Cheng Peng; Mingchao Yuan; Jinyan Huang; Zejun Wang; Jianhong Yu; Xiaoxiao Gao; Dan Wang; Xiaoqi Yu; Li Li; Jiayou Zhang; Xiao Wu; Bei Li; Yanping Xu; Wei Chen; Yan Peng; Yeqin Hu; Lianzhen Lin; Xuefei Liu; Shihe Huang; Zhijun Zhou; Lianghao Zhang; Yue Wang; Zhi Zhang; Kun Deng; Zhiwu Xia; Qin Gong; Wei Zhang; Xiaobei Zheng; Ying Liu; Huichuan Yang; Dongbo Zhou; Ding Yu; Jifeng Hou; Zhengli Shi; Saijuan Chen; Zhu Chen; Xinxin Zhang; Xiaoming Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-06       Impact factor: 11.205

8.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.

Authors:  Annemarie B Docherty; Ewen M Harrison; Christopher A Green; Hayley E Hardwick; Riinu Pius; Lisa Norman; Karl A Holden; Jonathan M Read; Frank Dondelinger; Gail Carson; Laura Merson; James Lee; Daniel Plotkin; Louise Sigfrid; Sophie Halpin; Clare Jackson; Carrol Gamble; Peter W Horby; Jonathan S Nguyen-Van-Tam; Antonia Ho; Clark D Russell; Jake Dunning; Peter Jm Openshaw; J Kenneth Baillie; Malcolm G Semple
Journal:  BMJ       Date:  2020-05-22

9.  A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.

Authors:  Ventura A Simonovich; Leandro D Burgos Pratx; Paula Scibona; María V Beruto; Marcelo G Vallone; Carolina Vázquez; Nadia Savoy; Diego H Giunta; Lucía G Pérez; Marisa Del L Sánchez; Andrea Vanesa Gamarnik; Diego S Ojeda; Diego M Santoro; Pablo J Camino; Sebastian Antelo; Karina Rainero; Gabriela P Vidiella; Erica A Miyazaki; Wanda Cornistein; Omar A Trabadelo; Fernando M Ross; Mariano Spotti; Gabriel Funtowicz; Walter E Scordo; Marcelo H Losso; Inés Ferniot; Pablo E Pardo; Eulalia Rodriguez; Pablo Rucci; Julieta Pasquali; Nora A Fuentes; Mariano Esperatti; Gerardo A Speroni; Esteban C Nannini; Alejandra Matteaccio; Hernán G Michelangelo; Dean Follmann; H Clifford Lane; Waldo H Belloso
Journal:  N Engl J Med       Date:  2020-11-24       Impact factor: 91.245

10.  Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia.

Authors:  Fan Wang; Jiayan Nie; Haizhou Wang; Qiu Zhao; Yong Xiong; Liping Deng; Shihui Song; Zhiyong Ma; Pingzheng Mo; Yongxi Zhang
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

View more
  8 in total

1.  CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence.

Authors:  Chiraphat Kloypan; Matthanaporn Saesong; Juthamat Sangsuemoon; Prawat Chantharit; Pajaree Mongkhon
Journal:  Eur J Clin Invest       Date:  2021-08-18       Impact factor: 5.722

2.  A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.

Authors:  Vasiliki Pappa; Anthi Bouchla; Evangelos Terpos; Thomas P Thomopoulos; Margherita Rosati; Dimitris Stellas; Anastasia Antoniadou; Andreas Mentis; Sotirios G Papageorgiou; Marianna Politou; Anastasia Kotanidou; Ioannis Kalomenidis; Garyfalia Poulakou; Edison Jahaj; Eleni Korompoki; Sotiria Grigoropoulou; Xintao Hu; Jenifer Bear; Sevasti Karaliota; Robert Burns; Maria Pagoni; Ioannis Trontzas; Elisavet Grouzi; Stavroula Labropoulou; Kostantinos Stamoulis; Aristotelis Bamias; Sotirios Tsiodras; Barbara K Felber; George N Pavlakis; Meletios- Athanasios Dimopoulos
Journal:  Microorganisms       Date:  2021-04-11

Review 3.  An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.

Authors:  H S C Paula; S B Santiago; L A Araújo; C F Pedroso; T A Marinho; I A J Gonçalves; T A P Santos; R S Pinheiro; G A Oliveira; K A Batista
Journal:  Braz J Med Biol Res       Date:  2021-12-10       Impact factor: 2.590

4.  Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response.

Authors:  Maddalena Marconato; Irene A Abela; Anthony Hauser; Magdalena Schwarzmüller; Rheliana Katzensteiner; Dominique L Braun; Selina Epp; Annette Audigé; Jacqueline Weber; Peter Rusert; Eméry Schindler; Chloé Pasin; Emily West; Jürg Böni; Verena Kufner; Michael Huber; Maryam Zaheri; Stefan Schmutz; Beat M Frey; Roger D Kouyos; Huldrych F Günthard; Markus G Manz; Alexandra Trkola
Journal:  J Clin Invest       Date:  2022-06-15       Impact factor: 19.456

Review 5.  The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review.

Authors:  Andri Frediansyah
Journal:  Clin Epidemiol Glob Health       Date:  2021-06-29

6.  Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study.

Authors:  Mohamed Abuzakouk; Khaled Saleh; Manuel Algora; Ahmad Nusair; Jawahir Alameri; Fatema Alshehhi; Sara Alkhaja; Mohamed Badr; Khaled Abdallah; Bruno De Oliveira; Ashraf Nadeem; Yeldho Varghese; Dnyaseshwar Munde; Shameen Salam; Baraa Abduljawad; Hussam Elkambergy; Ali Wahla; Ahmed Taha; Jamil Dibu; Ahmed Bayrlee; Fadi Hamed; Laila AbdelWareth; Nadeem Rahman; Jorge Guzman; Jihad Mallat
Journal:  J Clin Med       Date:  2021-05-14       Impact factor: 4.241

Review 7.  Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence.

Authors:  Stephen A Klassen; Jonathon W Senefeld; Katherine A Senese; Patrick W Johnson; Chad C Wiggins; Sarah E Baker; Noud van Helmond; Katelyn A Bruno; Liise-Anne Pirofski; Shmuel Shoham; Brenda J Grossman; Jeffrey P Henderson; R Scott Wright; DeLisa Fairweather; Nigel S Paneth; Rickey E Carter; Arturo Casadevall; Michael J Joyner
Journal:  Front Med (Lausanne)       Date:  2021-06-07

Review 8.  Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients.

Authors:  Mickael Beraud; Erin Goodhue Meyer; Miquel Lozano; Aicha Bah; Ralph Vassallo; Bethany L Brown
Journal:  Transfus Apher Sci       Date:  2022-01-13       Impact factor: 2.596

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.